Publications by authors named "A Essaadi"
Cell-based therapies constitute a real hope for the treatment of ischaemic diseases. One of the sources of endothelial progenitors for autologous cell therapy is Endothelial Colony Forming Cells (ECFC) that can be isolated from peripheral blood. However, their use is limited by their low number in the bloodstream and the loss of their stem cell phenotype associated with the acquisition of a senescent phenotype in culture.
View Article and Find Full Text PDFCD146 is an adhesion molecule present on many tumors (melanoma, kidney, pancreas, breast, ...
View Article and Find Full Text PDFArticle Synopsis
- CD146 expression in cancer cells is linked to cancer progression and poor prognosis, particularly in melanoma and pancreatic tumors.
- Soluble CD146 (sCD146) secreted by these cancer cells promotes tumor development by enhancing angiomotin levels and fostering both angiogenesis and cancer cell proliferation.
- A new monoclonal antibody targeting sCD146 shows promise in inhibiting tumor growth and vascularization in mouse models, suggesting that this strategy could be an effective treatment for CD146-positive tumors.
Aims: Endothelial colony-forming cells (ECFC) constitute an endothelial progenitor fraction with a promising interest for the treatment of ischaemic cardiovascular diseases. As soluble CD146 (sCD146) is a new factor promoting angiogenesis, we examined whether sCD146 priming could improve the therapeutic potential of ECFC and defined the involved mechanism.
Methods And Results: We investigated the effects of sCD146 priming on regenerative properties of ECFC in vivo.